TEVA Pharmaceutical Industries (NYSE: TEVA) insider transactions
In the twelve months to 10 November 2026, executives and directors of TEVA Pharmaceutical Industries reported 59 open-market sales of 3,319,082 shares ($111.2m) and 0 open-market purchases, by 15 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 5 November 2026 | Sabag Mark | See "Remarks" | Option exercise | +46,000 | $34.90 | 126,760 | Form 4 |
| 5 November 2026 | Sabag Mark | See "Remarks" | Open-market sale | −46,000 | $41.93 | 80,760 | Form 4 |
| 4 November 2026 | Bergwerk Dov | Interim Cheif Legal Officer | Option exercise | +17,505 | $34.70 | 29,448 | Form 4 |
| 4 November 2026 | Bergwerk Dov | Interim Cheif Legal Officer | Open-market sale | −17,505 | $41.72 | 11,943 | Form 4 |
| 4 November 2026 | Bergwerk Dov | Interim Cheif Legal Officer | Option exercise | +8,755 | $28.98 | 20,698 | Form 4 |
| 4 November 2026 | Bergwerk Dov | Interim Cheif Legal Officer | Open-market sale | −8,755 | $41.72 | 11,943 | Form 4 |
| 18 September 2026 | Mignone Roberto | Director | Open-market sale | −367,600 | $39.06 | 0 | Form 4 |
| 18 September 2026 | Savage Brian | Interim Chief Legal Officer | Option exercise | +4,503 | $34.70 | 15,842 | Form 4 |
| 18 September 2026 | Savage Brian | Interim Chief Legal Officer | Open-market sale | −4,503 | $38.69 | 11,339 | Form 4 |
| 18 September 2026 | Savage Brian | Interim Chief Legal Officer | Open-market sale | −2,525 | $39.15 | 8,814 | Form 4 |
| 18 September 2026 | Savage Brian | Interim Chief Legal Officer | Open-market sale | −314 | $38.70 | 8,500 | Form 4 |
| 21 August 2026 | Satchi-Fainaro Ronit | Director | Open-market sale | −415 | $37.25 | 111,986 | Form 4 |
| 21 August 2026 | Weiss Amir | Chief Accounting Officer | Open-market sale | −6,945 | $37.61 | 13,071 | Form 4 |
| 21 August 2026 | Weiss Amir | Chief Accounting Officer | Option exercise | +2,500 | $19.61 | 15,571 | Form 4 |
| 21 August 2026 | Weiss Amir | Chief Accounting Officer | Open-market sale | −2,500 | $37.63 | 13,071 | Form 4 |
| 17 August 2026 | Lippman Evan | EVP, Business Development | Open-market sale | −18,600 | $36.57 | 25,591 | Form 4 |
| 5 August 2026 | Zaks Tal Zvi | Director | Open-market sale | −17 | $34.87 | 73,247 | Form 4 |
| 3 August 2026 | Hughes Eric A | "See ""Remarks""" | Option exercise | +52,744 | — | 160,455 | Form 4 |
| 3 August 2026 | Hughes Eric A | "See ""Remarks""" | Open-market sale | −25,578 | $34.88 | 134,877 | Form 4 |
| 3 August 2026 | Jover Placid | "See ""Remarks""" | Option exercise | +12,827 | — | 19,601 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the TEVA Pharmaceutical Industries page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.